242 related articles for article (PubMed ID: 24447535)
1. The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors.
Gu Y; Chen T; López E; Wu W; Wang X; Cao J; Teng L
J Transl Med; 2014 Jan; 12():16. PubMed ID: 24447535
[TBL] [Abstract][Full Text] [Related]
2. Advances in the understanding of the structure and function of ER-α36,a novel variant of human estrogen receptor-alpha.
Rao J; Jiang X; Wang Y; Chen B
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):231-7. PubMed ID: 21888973
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
Wang ZY; Yin L
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
5. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling.
Wang Z; Zhang X; Shen P; Loggie BW; Chang Y; Deuel TF
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9063-8. PubMed ID: 16754886
[TBL] [Abstract][Full Text] [Related]
6. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
7. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
[TBL] [Abstract][Full Text] [Related]
8. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
9. ER-α36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells.
Sun Q; Liang Y; Zhang T; Wang K; Yang X
Biochem Biophys Res Commun; 2017 Jun; 487(3):625-632. PubMed ID: 28435071
[TBL] [Abstract][Full Text] [Related]
10. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
[TBL] [Abstract][Full Text] [Related]
11. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY
Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
13. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
[TBL] [Abstract][Full Text] [Related]
15. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas.
Lee LM; Cao J; Deng H; Chen P; Gatalica Z; Wang ZY
Anticancer Res; 2008; 28(1B):479-83. PubMed ID: 18383888
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-independent effects of ER-α36 in ER-negative breast cancer.
Zhang J; Li G; Li Z; Yu X; Zheng Y; Jin K; Wang H; Gong Y; Sun X; Teng X; Cao J; Teng L
Steroids; 2012 May; 77(6):666-73. PubMed ID: 22402113
[TBL] [Abstract][Full Text] [Related]
17. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.
Vranic S; Gatalica Z; Deng H; Frkovic-Grazio S; Lee LM; Gurjeva O; Wang ZY
J Clin Pathol; 2011 Jan; 64(1):54-7. PubMed ID: 21045236
[TBL] [Abstract][Full Text] [Related]
18. Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design.
Adewumi AT; Mosebi S
Biomolecules; 2023 Dec; 13(12):. PubMed ID: 38136668
[TBL] [Abstract][Full Text] [Related]
19. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma.
Qu C; Wang C; Li H; Li Y; Han C; Tao X; Guan X; Zhang Y; Chen M; Liu J; Zou W
Cell Biol Int; 2022 Nov; 46(11):1759-1774. PubMed ID: 35930599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
